# Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

> **NCT06957379** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 78 (actual)

## Conditions studied

- HR+/HER2- Advanced/Metastatic Breast Cancer

## Interventions

- **DRUG:** Letrozole
- **DRUG:** Anastrozole
- **DRUG:** Exemestane
- **DRUG:** Fulvestrant
- **DRUG:** Sirolimus for Injection (Albumin-bound)

## Key facts

- **NCT ID:** NCT06957379
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-29
- **Primary completion:** 2025-06
- **Final completion:** 2025-12
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2025-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06957379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06957379, "Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06957379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*